UNITED LAB(03933.HK): Tadalafil Tablets Approved for Marketing to Expand Layout in Men's Health Sector

NewTimeSpace · 2026/07/02 17:58 · By Jiayi Sun

NewTimeSpace News: The United Laboratories International Holdings Ltd (03933.HK) announced that tadalafil tablets (specifications: 5mg, 10mg, 20mg) filed by Zhongshan Branch of Zhuhai United Laboratories, its wholly-owned subsidiary, have obtained marketing approval from the National Medical Products Administration, indicated for the treatment of erectile dysfunction and erectile dysfunction accompanied by benign prostatic hyperplasia.

NewTimeSpace News: The United Laboratories International Holdings Ltd (03933.HK) issued a voluntary announcement dated 2 July 2026. Tadalafil tablets (specifications: 5mg, 10mg, 20mg) submitted by Zhongshan Branch of Zhuhai United Laboratories Co., Ltd., the Company’s wholly-owned subsidiary, have passed the marketing registration review and approval of the National Medical Products Administration, with approval numbers H20265009, H20265010 and H20265011 respectively.

Tadalafil tablet is a selective phosphodiesterase type 5 (PDE5) inhibitor, indicated for the treatment of erectile dysfunction and erectile dysfunction combined with benign prostatic hyperplasia. Compared with similar drugs, its core advantage lies in a long duration of efficacy up to 36 hours, and its efficacy will not be affected by food intake.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

UNITED LAB 03933.HK new drug launch